Kristina Burow Sells 3,053 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Kristina Burow sold 3,053 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total value of $164,068.22. Following the completion of the sale, the director directly owned 114,657 shares of the company’s stock, valued at approximately $6,161,667.18. This trade represents a 2.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Trading Up 0.9%

Scholar Rock stock traded up $0.48 during midday trading on Monday, hitting $55.36. 1,182,357 shares of the stock were exchanged, compared to its average volume of 1,407,918. The company has a fifty day simple moving average of $48.43 and a two-hundred day simple moving average of $46.59. Scholar Rock Holding Corporation has a 52 week low of $27.07 and a 52 week high of $56.54. The stock has a market capitalization of $6.63 billion, a PE ratio of -15.42 and a beta of 0.67. The company has a quick ratio of 8.64, a current ratio of 8.64 and a debt-to-equity ratio of 0.71.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter in the previous year, the company earned ($0.67) EPS. Equities research analysts anticipate that Scholar Rock Holding Corporation will post -3.23 EPS for the current fiscal year.

Institutional Trading of Scholar Rock

A number of institutional investors have recently modified their holdings of SRRK. AQR Capital Management LLC raised its position in Scholar Rock by 609.3% in the 1st quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock valued at $1,842,000 after buying an additional 49,217 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Scholar Rock by 12.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock valued at $1,709,000 after purchasing an additional 5,831 shares during the last quarter. Millennium Management LLC lifted its position in shares of Scholar Rock by 37.4% in the first quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock worth $6,438,000 after purchasing an additional 54,555 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Scholar Rock by 25.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock worth $5,460,000 after purchasing an additional 34,594 shares in the last quarter. Finally, Strs Ohio acquired a new position in Scholar Rock during the first quarter worth $77,000. 91.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

SRRK has been the topic of several research analyst reports. Wedbush raised their price objective on Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 1st. Canaccord Genuity Group initiated coverage on Scholar Rock in a report on Monday, April 20th. They issued a “buy” rating and a $62.00 price target for the company. HC Wainwright lifted their price objective on Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a report on Friday, May 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Finally, Barclays raised their target price on shares of Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $56.00.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).